Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery.
Read the full release
“The scale and pace in growth of human genetics data is an extraordinary semantic and computational challenge. We continue to marvel at Paradigm4’s ability to manage the ever-growing complexities in the day-to-day work of incorporating new genetics tool sets and the constant expansion of novel, diverse phenotypic data. We endeavour to be the leaders in developing genetically validated RNAi therapeutics and the REVEAL platform has made this possible.”
— Greg Hinkle, VP of Research Informatics, Alnylam
Get the case study
Chat with us to learn more
Our REVEAL integrative analytics software platform is transformative.
Our users have the proof:
- New drug targets and indications discovered in months
- The lowest cloud computing and storage costs
» See what else REVEAL delivers
Life Science Solutions LEARN MORE
Agile translational research with a suite of extensible, user-friendly apps.
“P4’s pQTL ran 40x faster and cost 30x less than the consortium’s run. [This] “Highlights the importance not just of biology but also computer science—your knowledge and ability to optimize is also key.”
— Principal Scientist, Computational Genomics, Top 10 Pharma
Agility Delivered
“The most advanced solution we have to bring together multiple data types and give easy access across all to our researchers… It’s refreshing when it just works.”
— Translational Medicine Bioinformatics Group Lead, Top 10 Pharma